Nature Communications

SEP 7, 2026 · JOURNAL ARTICLE

Glucose-induced histone lactylation confers metformin resistance in colorectal cancer stem cells

Nature Communications

A mechanistic study identifying a metabolic pathway and proposing drug targets, but without clinical efficacy data, human trials, or validation of the proposed combination therapy.

SEP 5, 2026 · JOURNAL ARTICLE

PRMT7 restricts CD8+ T cells expansion via the NF-ΚB pathway

Nature Communications

A mechanistically sound study combining genetic and pharmacological approaches in mouse and human models, demonstrating PRMT7 inhibition enhances CD8+ T cell function, but limited by single tumor model and lack of phase-controlled clinical trial.

SEP 3, 2026 · JOURNAL ARTICLE

Functional coupling between MC4R and Kir7.1 contributes to clozapine-induced weight gain in female mice

Nature Communications

Mechanistic study in a mouse model proposing a novel signaling pathway for clozapine-induced weight gain, without evidence of clinical translation or validation in humans.

SEP 2, 2026 · JOURNAL ARTICLE

Subtyping metabolic dysfunction-associated steatotic liver disease using electronic health record-linked genomic cohorts reveals diverse etiologies and progression

Nature Communications

A well-designed latent class analysis identifying five reproducible MASLD subtypes with distinct genetic and clinical profiles in independent cohorts, but a cross-sectional observational study without prospective clinical trials or hard outcome validation.

AUG 26, 2026 · JOURNAL ARTICLE

Methylation Mesa define functional regulatory elements for targeted gene activation

Nature Communications

This is a mechanistic discovery study identifying a novel epigenetic element class (Methylation Mesa) and demonstrating proof-of-concept that targeted demethylation drives gene activation in cell models, but lacks clinical endpoint data or confirmatory independent validation.

AUG 17, 2026 · JOURNAL ARTICLE

Global genomic surveillance uncovers emergence and spatiotemporal patterns of World Health Organization priority antibiotic resistance in invasive Salmonella

Nature Communications

A large retrospective genomic surveillance study describing resistance prevalence and trends across 7,691 isolates, but without clinical outcomes, intervention comparisons, or mechanistic validation to support practice-changing or strong evidence.

AUG 17, 2026 · JOURNAL ARTICLE

Engineered bacteria as exogenous organelle mimics restore PTEN and p53 tumor suppressor functions for cancer therapy

Nature Communications

This is a proof-of-concept study in murine melanoma using a novel engineered bacterial platform with surrogate endpoints; efficacy and safety in humans remain untested.

AUG 15, 2026 · JOURNAL ARTICLE

Sintilimab plus Bevacizumab biosimilar IBI305 and chemotherapy as a first-line treatment in advanced gastric or gastroesophageal junction adenocarcinoma (SBAGA): a single-arm, phase Ib/II study

Nature Communications

Single-arm Phase II trial with a clear efficacy endpoint (ORR 87.0%) and manageable safety profile, but lacks a randomized comparator and modest sample size, necessitating confirmation in larger RCTs.